BioLamina announces release of first batches from new facility

The transaction is valued at approximately USD 2.6 billion equity value and USD 2.5 billion net of cash, on a fully diluted basis.

IRLAB Therapeutics has announced that dosing has been initiated in a Phase I clinical study of the drug candidate IRL757 in healthy adults aged 65 and older.

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia.

The two companies have expanded their partnership to accelerate the development of the Dispersome technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules.

Xbrane Biopharma has received scientific advice from the US Food and Drug Administration (FDA) on the development of its Opdivo biosimilar candidate Xdivane.

AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting based on the positive results from the DESTINY-Breast06 Phase III trial which compared Enhertu to chemotherapy.